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High-dose chemotherapy with consecutive autologous stem cell transplantation (auto-
SCT) is a well-established treatment option for patients suffering from malignant lym-
phoma or multiple myeloma. Natural killer (NK) cells are an important part of the immune 
surveillance, and their cell number after autoSCT is predictive for progression-free and 
overall survival. To improve knowledge about the role of NK cells after autoSCT, we 
investigated different NK cell subgroups, their phenotype, and their functions in patients 
treated with autoSCT. Directly after leukocyte regeneration (>1000 leukocytes/μl) follow-
ing autoSCT, CD56++ NK cells were the major NK cell subset. Surprisingly, these cells 
showed unusually high surface expression levels of CD57 and killer Ig-like receptors (KIRs) 
compared to expression levels before or at later time points after autoSCT. Moreover, 
these NK cells strongly upregulated KIR2DL2/3/S2 and KIR3DL1, whereas KIR2DL1/
S1 remained constant, indicating that this cell population arose from more immature NK 
cells instead of from activated mature ones. Remarkably, NK cells were already able to 
degranulate and produce IFN-γ and MIP-1β upon tumor interaction early after leukocyte 
regeneration. In conclusion, we describe an unusual upregulation of CD57 and KIRs 
on CD56++ NK cells shortly after autoSCT. Importantly, these NK cells were functionally 
competent upon tumor interaction at this early time point.
Keywords: nK cells, cD57, Kir, autologous stem cell transplantation, cD107a expression, iFn-γ production
inTrODUcTiOn
Natural killer (NK) cells are an important part of the innate immune system and are able to 
kill virus-infected or malignantly transformed cells (1). Their important role in tumor sur-
veillance has been demonstrated in many different tumor models (1). NK cell cytotoxicity is 
regulated by a diverse repertoire of inhibitory and activating receptors. Inhibitory receptors, 
such as killer Ig-like receptors (KIRs) and the C-type lectin-like receptor NKG2A, recognize 
Abbreviations: HDC, high-dose chemotherapy; (auto)SCT, (autologous) stem cell transplantation; MM, multiple myeloma; 
NHL, non-Hodgkin lymphoma; TP1–3, time point 1–3; KIRs, killer Ig-like receptors; NK cell, natural killer cell.
November 2015 | Volume 6 | Article 5832
Jacobs et al. NK Cells After Autologous SCT
Frontiers in Immunology | www.frontiersin.org
different alleles of HLA molecules (HLA-A, B, and C by KIRs 
and HLA-E by NKG2A) on healthy cells. In contrast, many 
tumor cells downregulate their HLA molecules to evade T cell 
recognition, making them more susceptible to NK cell kill-
ing (2). Additionally, tumor cells may express stress-induced 
molecules, such as MHC I chain-related molecule A/B or 
UL-16-binding proteins, which are ligands for the activating 
NK cell receptor NKG2D (3, 4).
High-dose chemotherapy (HDC) with consecutive autologous 
stem cell transplantation (autoSCT) is an effective and well-
established treatment option for patients suffering from multiple 
myeloma (MM) (5) or malignant lymphoma (6–9). Before treat-
ment with the myeloablative chemotherapy, hematopoietic stem 
cells are collected from peripheral blood and frozen. Following 
HDC, these cells are thawed and given back to the patient in order 
to shorten the time of aplasia, thereby reducing the infection and 
blood transfusion rates.
Many reports have demonstrated the important role of the 
absolute lymphocyte count after HDC/autoSCT (10). It has been 
shown that an absolute lymphocyte count >500/μl is associated 
with improved overall and progression-free survival in patients 
with Hodgkin lymphoma (11), non-Hodgkin lymphoma (NHL) 
(12), acute myeloid leukemia (13), MM (12), and metastatic breast 
cancer (14). By analyzing the different lymphocyte subsets at day 
15 following autoSCT, a clear correlation between improved over-
all survival and progression-free survival could only be found 
for NK cell counts >80/μl. No correlation was found for any 
other lymphocyte subset (15). In a more recent study, improved 
median overall and progression-free survival as well as the NK 
cell count at day 15 after HDC/autoSCT were all associated with 
an increased IL-15 concentration at day 15 of ≥76.5 pg/ml for 
NHL patients receiving HDC/autoSCT (16).
Because there is no information available regarding the 
detailed analysis of NK cell subsets or function early after HDC/
autoSCT, in our study, we prospectively investigated the major 
NK cell subsets directly after leukocyte recovery (leukocytes 
>1000/μl) and also at later time points after HDC/autoSCT in 
patients with different lymphoproliferative diseases. Moreover, 
we further analyzed the different NK cell subsets, evaluating 
their education and differentiation markers, as well as their 
functional properties, such as cytokine/chemokine production 
and degranulation capacity.
MaTerials anD MeThODs
Patients’ characteristics and  
study Design
This study was carried out in accordance with the recommenda-
tions of the local ethics committee of the University of Erlangen, 
and all patients gave written informed consent in accordance 
with the Declaration of Helsinki. Patients who suffered from 
MM or malignant lymphoma and received HDC/autoSCT were 
included. Blood was taken from these patients at three different 
time points. Time point 1 (TP1) was before the start of the HDC 
and at least 3 weeks after the last chemotherapy. The second time 
point (TP2) was 1–2  days after leukocyte regeneration (>1000 
leukocytes/μl) following autoSCT, and the third time point (TP3) 
was after at least 2 weeks following leukocyte recovery.
reagents
For NK and K562 cell culture, we used full media containing 
RPMI 1640 media (Gibco®) supplemented with 10% FBS, MEM 
non-essential amino acids (1%), sodium pyruvate (1%), l-glu-
tamine (1%; all from PanBiotech), and penicillin/streptomycin 
(1%; Thermo Fischer Scientific). For the washing steps, we used 
Dulbecco’s phosphate-buffered saline (DPBS; Gibco®).
To analyze the different leukocyte subsets, CD3, CD14, CD16, 
CD19, CD45, and CD56 antibodies with different fluorochromes 
from Becton Dickinson (BD) were used. For detailed NK cell sub-
set analyses, we used anti-KIR2D-, KIR3DL1/2-, and KIR2DL1/
S1-PE (Miltenyi), KIR2DL1-PerCP (R&D), KIR2DL2/3/S2-APC 
(Beckman Coulter), KIR3DL1 PE-Vio770 (Miltenyi), NKG2A 
FITC (Miltenyi), and CD57 APC (BD). For the KIR staining, the 
clones of the antibodies were selected according to Czaja et al. 
(17), and a sequential staining protocol was used as described 
by Beziat et  al. (18). For intracellular staining, we used IFN-γ 
PE-Cy-7 and MIP-1β APC-H7 (BD). To exclude dead cells, 
7-AAD (BD) for extracellular and Fixable Viability Dye eFluor® 
520 (eBioscience) for intracellular staining were used.
PBMc Preparation, Freezing, and Thawing
Blood samples were obtained from the patients at the indicated 
time points. PBMCs were isolated by performing a Ficoll density 
centrifugation of whole blood samples, and then the PBMCs 
were frozen (5 × 106 PBMCs/ml freezing media containing 90% 
FCS + 10% DMSO; from Sigma) until they were used.
For thawing, tubes were incubated at room temperature and 
gently thawed by re-suspending the cells in prewarmed full media 
(without FCS). The cells were washed twice and counted before 
being used for further analysis.
extra- and intracellular antibody staining
For surface staining, the cells were incubated with different anti-
body cocktails for 10′ at 4°C; then, they were washed and either 
fixed in BD CytoFix™ solution or further processed for intracel-
lular staining using the BD Cytofix/Cytoperm™ kit. Briefly, the 
cells were first incubated for 30′ at 4°C with Fixable Viability Dye 
eFluor® 520 (eBioscience), and then they were washed and fixed 
for 20′ at 4°C in 100 μl BD Cytofix™ solution. Subsequently, the 
cells were washed in BD Cytoperm™ solution and incubated 
with the indicated intracellular antibodies for 20′ at 4°C. Finally, 
the cells were washed, placed into BD CytoFix™ solution, and 
analyzed with a BD FACSCanto II™ or Canto10c™ using the 
FlowJo® software (FlowJo, LLC) was used to analyze the FACS 
data.
Functional assays
After thawing, the cells were placed into full media supplemented 
with 100 IU IL-2/ml (Proleukin®, Novartis) in a 96-U well plate 
overnight. The cells were harvested, washed, counted, and 
incubated with K562 cells (ratio 1:1) in full media in a 96-U well 
plate for 4 h. CD107a APC (BD) was added at the start of the 
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coculturing period and BD GolgiStop™ (BD) was added after 1 h 
for the rest of the incubation time.
statistics
For statistical analysis, we used GraphPad Prism® software. In 
all graphs, the mean and SD were calculated and plotted. For 
comparison between matched samples, we used a Wilcoxon 
test, whereas for non-matched samples, we performed a Mann–
Whitney test. Statistical significance is indicated with the p-values 
(*<0.05; **<0.01; ***<0.001; *****<0.0001).
resUlTs
Patients’ characteristics and leukocyte 
subsets
Peripheral blood samples from 32 different patients collected 
at three specific time points (TP1–3, as described in Section 
“Materials and Methods”) were available for the analysis of leu-
kocyte subsets. The basic patient characteristics are summarized 
in Table  1. The ratio between male and female patients was 
approximately 2:1. Half of the patients suffered from MM. The 
average age at HDC/autoSCT was 56.7 years. The average time 
between SCT and TP2 was 11.6 days, whereas the time between 
collecting samples at TP2 and TP3 was 38.8 days. All three values 
were normally distributed.
Before the start of HDC/autoSCT at TP1, CD3+CD56− T cells 
and CD14+ monocytes were the two major leukocyte subsets 
in all patients (Figure  1A; for gating strategy, see Figure S1 in 
Supplementary Material). While CD14+ monocytes were the 
major subset early after leukocyte recovery after HDC/autoSCT 
at TP2 (Figures 1A,B), CD3+CD56− T cells were the major sub-
set at TP3 (Figures 1A,B). In contrast, the NK cell percentages 
within the leukocyte population significantly decreased from TP1 
to TP2 (p-value: 0.0175) but recovered to the initial value at TP3 
(p-value TP2/TP3: 0.0263; TP1/3: 0.19; Figures 1A,B).
By correlating the NK cell dynamics at the three different 
time points with clinical data, we observed that the fold change 
of the NK cell percentage within the leukocyte population 
between TP1 and TP2 (ratio TP2/TP1) significantly differed 
between patients having a time period of ≤11  days between 
SCT and TP2 and those having a period of >11 days (p-value: 
0.04). When the time period was >11 days, no decrease in the 
TaBle 1 | Patient characteristics.
gender Male (23), female (9)
Mean age (range) 56.7 years (30–74 years)
Malignancy
Multiple myeloma 16
Diffuse large-cell B cell lymphoma 7
Mantle cell lymphoma 3
T cell lymphoma 5
Hodgkin lymphoma 1
recurrent/refractory disease at 1 year 
after scT (yes/no)
6/21 (5 patients were lost during 
follow-up)
Time period scT–TP2 (mean, days) 11.6
Time period TP2–TP3 (mean, days) 38.8
NK cell percentage within the leukocyte population at TP2 
was observed. Moreover, another significant difference was 
observed when comparing the fold change in the NK cell per-
centage between TP1 and TP2 in patients who were refractory/
recurrent or not at 1 year after SCT (p-value: 0.0258). Patients 
with recurrent or refractory disease did not have a decrease 
in their fold change ratio (TP2/TP1), while patients without 
recurrent/refractory disease did have a decrease at 1 year after 
SCT. Additionally, the fold increase in the NK cell percentage 
between TP2 and TP3 (TP3/TP2 ratio) was more pronounced 
when the time period between TP2 and TP3 was ≤38  days 
(p-value: 0.12; Figure 1C).
No differences were observed when analyzing the patients’ age 
or hematological malignancies in relation to the fold changes of 
the NK cell percentages within the leukocyte population between 
the three different time points (Figure S2 in Supplementary 
Material).
cD56++cD16−/+ nK cells are the Major 
subset at leukocyte recovery
Next, we analyzed the different NK cell subsets based on 
their CD56 and CD16 expression. NK cells were divided into 
CD56++CD16− or CD16+ and CD56+CD16++ NK cells (see Figure 
S1 in Supplementary Material). The CD56++CD16+ population has 
been reported to be an intermediate state between CD56++CD16− 
and CD56+CD16++ NK cells (19, 20). The CD56+CD16− popula-
tion was excluded, as it was shown that this population could be 
induced by cryopreservation (21).
At TP1, the major NK cell subset was the CD56+CD16++ 
NK cell population (71.86%), followed by the CD56++CD16+ 
(17.71%) and the CD56++CD16− (10%) populations (Figure 2A). 
After leukocyte regeneration (TP2), the CD56+CD16++ cells 
significantly decreased (39.98%; p-value: <0.0001), whereas both 
CD56++ NK cell subsets significantly increased (CD16−: 22.85%, 
p-value: <0.0001; CD16+: 36.51%, p-value: <0.0001). At TP3, the 
levels of CD56+CD16++ NK cells increased again (64.85%; p-value: 
<0.0001) but remained reduced in contrast to the starting levels 
at TP1 (p-value: 0.0064). Conversely, the levels of CD56++CD16− 
(14.41%; p-value: 0.0006) and CD16+ (20.66%; p-value: <0.0001) 
cells decreased but remained significantly elevated compared 
to the starting values [p-values: 0.0184 (CD16−) and 0.0428 
(CD16+); Figure 2B].
The ratio between mature CD56+ and more immature CD56++ 
NK cells, which is approximately 10 within healthy donors (data 
not shown), was already significantly reduced within our patients 
before HDC/autoSCT (TP1; ratio: 3.707) because all patients 
had previously received chemotherapy. Nevertheless, the ratio 
significantly dropped at TP2 (ratio: 1.157; p-value: <0.0001) and 
did not recover to initial values at TP3 [ratio: 2.49; p-value: 0.0001 
(TP2–3); 0.0111 (TP1–3); Figure 2C].
The CD56+/CD56++ ratios at TP2 and TP3 were both inde-
pendent of the time period between SCT and TP2 (≤11  days: 
1.247 vs. >11  days: 1.041; p-value: 0.392) and between TP2 
and TP3 (≤38  days: 2.59 vs. >38  days: 2.32; p-value: 0.504; 
Figure  2D). Within the group of MM patients, the CD56+/
CD56++ ratio was lower compared to lymphoma patients, but 
FigUre 1 | (a) The percentages of the different leukocyte subsets within the leukocyte population at all three time points are indicated. (B) The percentage of 
CD14+ monocytes within the leukocyte population increased from TP1 (43.49%) to TP2 (61.22%; p-value: 0.0003), becoming the major leukocyte subset at TP2 but 
decreased below the starting levels at TP3 (34.6%; p-value TP2/TP3: <0.0001; TP1/3: 0.0088). In contrast, the T cell percentages decreased from TP1 (37.89%) to 
TP2 (22.5%; p-value: <0.0001), but they increased again at TP3 (48.49%) above the initial values to become the major leukocyte subset at TP3 (p-value TP2/TP3: 
<0.0001; TP1/3: 0.0093). The NK cell percentages decreased from TP1 (8.94%) to TP2 (7.32%) but reached the initial levels again at TP3 (8.29%). (c) Patients with 
a time period of ≤11 days between SCT and TP2 had a decrease from TP1 to TP2 within their NK cell percentage (ratio TP2/TP1: 0.49), in contrast to patients with 
a time period >11 days (ratio TP2/TP1: 1.07). Similarly, patients with no recurrent/refractory disease 1 year after SCT had a decrease of their NK cell percentage at 
TP2 (ratio TP2/TP1: 0.66), as opposed to patients who were recurrent/refractory at 1 year (ratio TP2/TP1: 1.28). The increase of the NK cell percentage from TP2 to 
TP3 was more pronounced in patients with a time period of ≤38 days between TP2 and TP3 (ratio TP3/TP2: 3.73) than in patients with a time period of >38 days 
(ratio TP3/TP2: 1.97).
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it was only significantly lower at TP2 (1.656 vs. 0.6578; p-value: 
0.0019; Figure  2D). In contrast, the patients’ age and relapse/
refractory status at 1  year after autoSCT seemed to have no 
impact on the CD56+/CD56++ ratio at any time point (Figure S3 
in Supplementary Material).
increased levels of cD57 and Kir 
expression after leukocyte regeneration
Next, we analyzed the expression of markers for NK cell educa-
tion and differentiation at the indicated time points.
As expected, the NKG2A expression on all NK cells increased 
from TP1 (67.63%) to TP2 (76.51%; p-value: 0.0179), and the 
percentage of NKG2A+ NK cells remained elevated above the 
starting values until TP3 (77.67%; p-value: 0.0009). Further NK 
cell subset analyses revealed that the observed early increase 
in NKG2A at TP2 was potentially an effect of the elevated 
CD56++ population expressing higher levels of NKG2A than the 
CD56+CD16++ population because the NKG2A expression did 
not significantly differ within the distinct subsets between TP1 
and TP2. In contrast, the percentage of NKG2A-expressing NK 
cells was significantly elevated in all subsets at TP3 compared to 
FigUre 2 | (a,B) The level of CD56+CD16++ NK cells significantly dropped at TP2 (39.98%) and recovered at TP3 (64.58%), but it remained lower in contrast to the 
starting levels (TP1: 71.86%). Moreover, the percentages of CD56++CD16−/+ NK cells were markedly increased at TP2 (CD16−: 22.85%; CD16+: 36.51%) and 
remained elevated at TP3 (CD16−: 14.41%; CD16+: 20.66%) compared to the TP1 values (CD16−: 10%; CD16+: 17.71%). (c) The ratio of CD56+/CD56++ NK cells 
at TP1 was already lower than in healthy controls (approx 10; data not shown), with a ratio of 3.707, and decreased further at TP2 (1.157). Although the ratio 
increased at TP3 (2.49), it was still lower compared to TP1 and healthy control samples. (D) There were no significant differences when analyzing the CD56+/CD56++ 
ratio at TP2 with regard to the time period between SCT and TP2 (≤11 days: 1.247; >11 days: 1.041) or at TP3 with regard to the period between TP2 and TP3 
(≤38 days: 2.59; >38 days: 2.32). A significant difference of the CD56+/CD56++ ratio between lymphoma and myeloma patients was only observed at TP2 
(lymphoma patients: 1.656; myeloma patients: 0.6578).
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TP1 [p-value: 0.0054 (CD56++CD16−); 0.0259 (CD56++CD16+); 
0.0031 (CD56+CD16++); Figure 3A].
CD57+ NK cells, known to define terminally differentiated NK 
cells, significantly increased from TP1 (43.53%) to TP2 (56.66%; 
p-value: 0.0163) in all NK cells but decreased to the initial values 
at TP3 (39.13%; p-value: 0.4274). Surprisingly, CD57 expression 
was significantly increased within the CD56++CD16+/− popula-
tion at TP2 (CD16−: 32.98%; CD16+: 57.78%, p-value: <0.0001) 
but decreased again from TP2 to TP3 (CD16−: 5.592%; CD16+: 
19.06%, p-value: <0.0001). Nevertheless, the percentage of 
CD57+ cells was still elevated in contrast to the starting values 
at TP1 [CD16−: 4.1%; CD16+: 15.58%, p-values: 0.0102 (CD16−); 
0.0214 (CD16+)]. CD57 expression within the CD56+CD16++ 
population was also elevated at TP2 (72.15%; p-value: 0.0006) 
but to a much lesser extent (Figure 3B).
Strikingly, the percentage of KIR+ NK cells remained constant 
over time (TP1: 42.45%; TP3: 44.09%; p-value: 0.463), even 
shortly after leukocyte regeneration (TP2: 40.77%; p-value: 
0.4106). Of note, the KIR expression within the CD56++CD16+/− 
NK cell population was markedly increased at TP2 (CD16−: 
FigUre 3 | (a) NKG2A expression was significantly increased at TP2 (76.41%) and TP3 (77.67%) within all NK cells compared to the starting values (TP1: 67.63). 
Moreover, the percentage of NKG2A+ cells was significantly increased at TP3 within the CD56++CD16− (TP1: 89.94%; TP3: 93.1%) and CD16+ (TP1: 87.6%; TP3: 
92.27%) subsets as well as within the CD56+CD16++ subset (TP1: 60.39%; TP3: 71.42%). (B) Similarly, the percentage of CD57+ NK cells increased at TP2 
(56.66%) but returned to the initial values at TP3 (TP1: 43.53%; TP3: 39.13%). Consistently, within the CD56++CD16− and CD16+ as well as within the 
CD56+CD16++ NK cell subsets, there was a highly significant increase of CD57 expression at TP2 (CD56++CD16−: 32.98%; CD56++CD16+: 57.78%; and 
CD56+CD16++: 72.15%), which decreased at TP3 again but remained above the starting values within the CD56++ subsets (CD16−: TP1 4.1% and TP3 5.592% and 
CD16+: TP1 15.58% and TP3 19.06%). (c) In parallel, the KIR expression was significantly elevated at TP2 (CD16−: 19.35%; CD16+: 42.14%) and TP3 (CD16−: 
10.43%; CD16+: 28.14%) compared to TP1 (CD16−: 7.82%; CD16+: 22.44%) within the CD56++ subsets but not within the CD56+CD16++ cells  
(TP1: 51.42%; TP2: 52.89%; and TP3: 55.23%).
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19.35%; CD16+: 42.14%; p-value: <0.0001 for both populations) 
and remained elevated at TP3 (CD16−: 10.43%; CD16+: 28.14%) 
in comparison to the starting values at TP1 [CD16−: 7.82%; 
CD16+: 22.44%; p-values: 0.0083 (CD16−); 0.0015 (CD16+)]. KIR 
expression within the CD56+CD16++ population remained stable 
throughout all time points (TP1: 51.42%, TP2: 52.89%, and TP3: 
55.23%; Figure 3C).
elevated cD57 and Kir expression is age 
Dependent
Additionally, we analyzed the influence of different clinical 
factors on the expression levels of NKG2A, CD57, and KIRs 
within the different NK cell subsets. As CD57 expression levels 
within healthy individuals are known to be age dependent (22), 
we compared CD57 expression within the younger (≤56 years) 
and older (>56 years) patient populations. Notably, there was a 
significant difference in the percentage of CD57+ cells within the 
CD56++CD16− population at TP2 (≤56 years: 23.98%; >56 years: 
42.8%; p-value: 0.0056), whereas this effect was not observed 
within the CD56++CD16+ or the CD56+CD16++ population 
(Figure 4A).
Similar, by analyzing KIR expression within the CD56++CD16+/− 
populations, we observed a significant difference in their expres-
sion at TP2 between the two age groups [≤56  years: 14.74% 
(CD16−) and 37.29% (CD16+); >56 years: 24.39% (CD16−) and 
47.44% (CD16+); p-values: 0.0088 (CD16−), 0.0317 (CD16+)]. No 
age-dependent difference was found for KIR expression within 
the CD56+CD16++ population at TP2 but at TP3 (≤56  years: 
50.51%; >56 years: 60.37%; p-value: 0.0225; Figure 4B).
In contrast, there was no difference in NKG2A expression 
throughout all age groups, time points, or NK cell populations 
(Figure 4C).
We also addressed CD57, KIR, and NKG2A expressions in 
different subsets with regard to recurrent/refractory disease at 
1 year after SCT and hematological malignancy. There were no 
differences in the expression of the three markers regarding the 
rate of relapsed/refractory disease throughout all NK cell subsets 
and time points, except for CD57 expression at TP1 within the 
CD56++CD16− NK cell population, which was higher in patients 
FigUre 4 | (a) There was a significant difference in the average of CD57+ cells within the CD56++CD16− NK cell subsets at TP2 in patients ≤56 years (23.98%) vs. 
>56 years (42.8%). A significant difference was not observed within the CD56++CD16+ (≤56 years: 50.83% vs. >56 years: 65.36%) or the CD56+CD16++ subset 
(≤56 years: 70.25% vs. >56 years: 74.23%). (B) The percentage of KIR+ NK cells at TP2 differed significantly between the two age groups within the CD56++ subset 
(≤56 years: CD56++CD16−: 14.74% and CD56++CD16+: 37.29% vs. >56 years: CD56++CD16−: 24.39% and CD56++CD16+: 47.44%). A significant difference within 
the CD56+CD16++ subset was observed at TP3 (≤56 years: 50.51% vs. >56 years: 60.37%). (c) No difference was observed in NKG2A expression within the 
different NK subsets and age groups.
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with no recurrent/refractory disease 1 year after SCT (p-value: 
0.0083; Figure S4A in Supplementary Material).
Furthermore, patients with MM had higher NKG2A expres-
sion within the CD56++CD16−/+ subset at TP2 compared to 
lymphoma patients. No further differences were observed (Figure 
S4B in Supplementary Material).
Detailed Kir expression analysis
We next performed an extended KIR analysis within the sam-
ples of five additional patients, who were not included into the 
original analysis group because we did not have a sample from 
TP3. We analyzed the expression levels and distribution of global 
KIR expression (anti-KIR2D and anti-KIR3DL1/2), as well as 
KIR2DL1/S1, KIR2DL2/3/S2, and KIR3DL1, within the different 
subsets at TP1 and TP2. Notably, global KIR expression levels 
were upregulated within both CD56++ NK cell populations at 
TP2 compared to TP1, whereas they remained stable within the 
CD56+CD16++ NK cell population, confirming the results from 
the former analyzed patient cohort (Figures  5A–C). Within 
the CD56+CD16++ population, no clear differences between 
the expression levels of the different KIR subsets were observed 
comparing TP1 and TP2 (Figure 5C). In contrast, both CD56++ 
NK cell subsets upregulated their KIR2DL2/3/S2 and KIR3DL1 
expression levels from TP1 to TP2, whereas the KIR2DL1/S1 levels 
FigUre 5 | (a) Global KIR expression (anti-KIR2D and anti-KIR3DL1/2) was upregulated within the CD56++CD16− NK cell population from TP1 to TP2 (TP1: 
13.56%; TP2: 29.04%). KIR2DL1/S1 remained stable (TP1: 3.33%; TP2: 3.2%), whereas KIR2DL2/3/S2 (TP1: 6.49%; TP2: 12.08%) and KIR3DL1 (TP1: 5.85%; 
TP2: 14.54%) were both upregulated. (B) Within the CD56++CD16+ NK cells, the global KIR expression was upregulated from TP1 to TP2 (TP1: 33.74%; TP2: 
54.24%) in addition to the KIR2DL2/3/S2 (TP1: 22.95%; TP2: 39.28%) and KIR3DL1 expression (TP1: 16.25%; TP2: 25.02%). In contrast, the KIR2DL1/S1 levels 
remained stable (TP1: 8.95%; TP2: 9.44%). (c) The expression levels of global KIR expression (TP1: 62.24%; TP2: 63.66%) as well as that of KIR2DL1/S1 (TP1: 
14.65%; TP2: 14.26%) remained stable, whereas the two other KIR subsets revealed a slight decrease from TP1 to TP2 within the CD56+CD16++ NK cell population 
[2DL2/3/S2: 48.4% (TP1) and 42.65% (TP2); 3DL1: 31.77% (TP1) and 22.88% (TP2)]. The proportions of the different KIR subsets within the whole KIR population 
are indicated within the pie charts (a–c).
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remained stable between the two time points (Figures  5A,B). 
Moreover, the proportion of the different KIR subsets within 
the global KIR population changed within the CD56++CD16− 
population, with KIR2DL2/3/S2 being the dominant KIR subset 
at TP1 and KIR3DL1 being the dominant one at TP2 (Figure 5A; 
pie chart). Within the CD56++CD16+ population, KIR2DL2/3/S2 
was the dominant KIR population at TP1 and was the only one to 
increase from TP1 to TP2 (Figure 5B; pie chart).
nK cell Function is Preserved after 
leukocyte recovery
Finally, we analyzed the functions of the different NK cell subsets 
at the three time points before and after HDC/autoSCT. After an 
overnight incubation with low-dose IL-2 (100 IU/ml) and 4 h of 
coculture with K562 cells, we investigated the cytokine (IFN-γ) 
and chemokine (MIP-1β) productions, as well as the NK cell 
degranulation (CD107a expression) capacity (for gating strategy 
see Figure S5 in Supplementary Material). Due to very low cell 
numbers at TP2, functional analysis was only possible in a subset 
of all included patients (n = 17).
As expected, CD56++CD16− NK cells were the main subset 
to produce IFN-γ upon interaction with K562 cells at all three 
time points (Figure  6A). The percentage of IFN-γ-positive 
CD56++CD16− NK cells was slightly decreased at TP2 compared 
to TP1 but significantly increased from TP2 to TP3 (p-value: 
0.0008). Similarly, MIP-1β- and CD107a-positive CD56++CD16− 
cells remained constant between TP1 and TP2, whereas their 
percentages increased from TP2 to TP3 [p-values: 0.0056 (MIP-
1β) and 0.0232 (CD107a)].
Whereas IFN-γ production was only marginal at all three time 
points within the CD56++CD16+ NK cell population (Figure 6B), 
MIP-1β- and CD107a-positive cells had similar percentages at 
TP1 and TP2. Both percentages significantly increased from TP2 
to TP3 (p-value: 0.0079 for both).
FigUre 6 | (a) The CD56++CD16− subset revealed an increase of IFN-γ-, MIP-1β-, and CD107a-positive cells between TP2 and TP3 [TP2: 4.9% (IFN-γ), 15.17% 
(MIP-1β), 34.37% (CD107a), TP3: 11.58% (IFN-γ), 22.58% (MIP-1β), 43.82% (CD107a)], while the percentages between TP1 and TP2 were similar [TP1: 7.92% 
(IFN-γ), 16.89% (MIP-1β), and 32.7% (CD107a)]. (B) IFN-γ-positive cells within the CD56++CD16+ population were only marginal at all three time points (TP1: 1.29%; 
TP2: 1.01%; TP3: 1.72%), whereas MIP-1β- and CD107a-positive cells increased from TP2 to TP3 [TP2: 13.26% (MIP-1β), 25.78% (CD107a); TP3: 18.37% 
(MIP-1β), 35.26% (CD107a)] but not from TP1 to TP2 [TP1: 14.79% (MIP-1β), 27.64% (CD107a)]. (c) No IFN-γ-positive cells were detectable within the 
CD56+CD16++ population at any of the three time points. MIP-1β-positive cells remained stable throughout all three time points (TP1: 8.93%; TP2: 10.06%; TP3: 
10.18%) which is similar to CD107a-expressing cells (TP1: 14.26%; TP2: 16.47%; TP3: 19.33%). (D) Patients were grouped according to the duration between 
SCT and TP2 (≤11 vs. >11 days). While there were no differences between the percentage of CD107a-expressing cells within the CD56++CD16− population at TP1 
and TP2, the percentage of CD107a-positive NK cells at TP2 was lower within patients with a longer duration between SCT and TP2 within the CD56++CD16+ 
(≤11 days: 30.74%; >11 days: 16.68%) and the CD56+CD16++ (≤11 days: 19.34%; >11 days: 11.21%) populations.
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Within the CD56+CD16++ NK cell subsets, the percentage of 
MIP-1β- and CD107a-positive NK cells after coincubation with 
K562 cells remained constant at all three time points, whereas 
no IFN-γ-positive NK cells were detected at any time point 
(Figure 6C).
Although the number of available patient samples was low, we 
tried to correlate the NK cell function values with clinical data. 
Remarkably, there was an impact of the duration from SCT to 
TP2 (≤11 vs. >11 days), as the percentage of CD107a-positive 
cells within the CD56++CD16+ and CD56+CD16++ populations 
was significantly lower when the time period between SCT and 
TP2 exceeded 11 days [p-values: 0.0111 (CD56++CD16+); 0.027 
(CD56+CD16++); Figure 6D]. In investigating age-dependent dif-
ferences (≤56 vs. >56 years), we observed that patients older than 
56 years tended to have slightly higher percentages of IFN-γ- and 
MIP-1β-positive CD56++CD16− cells at TP1, although the differ-
ence was not significant. Furthermore, no significant differences 
in the presence of MIP-1β- or CD107a-positive CD56++CD16+ 
or CD56+CD16++ NK cells between the two age groups were 
observed at all three time points, although older patients tended 
to have lower CD107a expression within the CD56+CD16++ 
subset at TP3 (p-value: 0.074). Notably, the observed increase 
of CD107a-positive CD56+CD16++ cells from TP2 to TP3 was 
only present in younger but not older patients [≤56 years: 15.69% 
(TP2) and 24.05% (TP3), p-value: 0.1; >56 years: 17.16% (TP2) 
and 15.14% (TP3), p-value: 0.82; Figure S6 in Supplementary 
Material].
DiscUssiOn
In the setting of HDC/autoSCT, it has been demonstrated that a 
rapid NK cell recovery at 1 month after HDC/autoSCT is associ-
ated with a prolonged progression-free survival in MM (23) and 
NHL patients (16). In those studies, the absolute NK cell count 
(cells/μl) at 1 month or 15 days after HDC/autoSCT was investi-
gated, whereas in our study, we analyzed the NK cell percentage 
within the leukocyte population in correlation with the day of 
leukocyte recovery following autoSCT.
Our data demonstrate that the percentage of NK cells within 
the leukocyte population decreased after leukocyte recovery but 
increased to the initial levels over time. Notably, when the time 
period between SCT and TP2 was >11 days, indicating a delay 
in leukocyte recovery, the decrease within the NK cell percent-
age was lower. This may be explained by the fact that leukocyte 
recovery (white blood cell count >1000/μl) after SCT is mainly 
due to the recovery of neutrophil granulocytes (10), and their 
recovery can be delayed in contrast to NK cell recovery (24). 
Moreover, the higher increase of the NK cell percentage from 
TP2 to TP3 in patients from whom the third blood sample was 
collected ≤38 days after TP2 indicates that the NK cell percentage 
within the leukocytes increases much more within the first month 
after leukocyte recovery and then decreases again. Similar results 
have been demonstrated by Rueff et al. by analyzing the absolute 
NK cell count numbers (cells/μl) 1, 3, 6, 12, and 24 months after 
SCT. Here, the NK cell numbers first increased 1 month after SCT, 
but then they decreased again until 6 months after SCT (23). The 
absence of a decrease in the NK cell percentage at TP2 within 
patients with recurrent/refractory disease at 1  year after SCT 
could be explained by the fact that most of these patients (4/6; 
66.6%) had a time period of >11 days from SCT to TP2, unlike 
non-relapsing/refractory patients (8/21; 38%).
In line with other NK cell reconstitution studies after SCT 
(24–26), we observed elevated percentages of the more immature 
CD56++CD16+/− NK cell subsets shortly after SCT, decreasing 
only slowly at later time points. As the ratio between CD56+/
CD56++ NK cells did not differ with shorter (≤38 days) or longer 
(>38 days) time periods between TP2 and TP3, we assume that 
normalization of the NK cell subset distribution takes much 
longer than the recovery of the NK cell numbers. Similar observa-
tions have been made within patients receiving an allogeneic SCT 
after reduced-intensity conditioning (26). The conditioning and 
former treatment regimens could explain the different NKG2A+  
NK cells ratios between myeloma and lymphoma patients at TP2.
Moreover, the percentage of NKG2A+ NK cells was increased 
after HDC/autoSCT and remained high even after several 
months, as it has been recently demonstrated by Pical-Izard et al. 
after allogeneic SCT (26). In contrast, we could demonstrate a 
highly significant increase of CD57+ and KIR+ NK cells, mainly 
within the CD56++CD16+/− subsets at TP2. This effect has not 
been described thus far within the literature because most of 
the studies have evaluated NK cell subsets 1  month after SCT 
(23–27). At this time point, the percentage of CD57+ and KIR+ 
NK cells had already decreased back toward normal levels 
within our study group. The prolonged immature phenotype in 
the Pical-Izard study may be attributed to GVHD prophylaxis, 
especially cyclosporine A (CSA). Vukicevic et al. investigate the 
NK cell phenotype at an equally early time point after allogeneic 
stem cell transplantation as we did but did not detect an upregu-
lation of KIRs within the CD56++ subsets (28), which might 
be due to the allogeneic transplantation setting. Acquisition of 
CD57 and KIRs as well as downregulation of NKG2A has been 
demonstrated as signs of NK cell differentiation and maturation 
(22). It is known that CD57 expression increases with age within 
the CD56+CD16++ population (29), whereas we did not observe 
any age-related differences within this NK cell subset at any time 
point. Nevertheless, an age-dependent difference was observed at 
TP2 within the CD56++CD16− population.
Therefore, the question arises whether these CD56++ cells 
described here represent more mature new NK cells or are just 
activated “old” NK cells that might have increased their CD56 
expression and lost CD16 on their surface. As this phenotype 
is reset after at least 2 weeks after leukocyte regeneration, one 
could argue that the phenotype shift is due to the cytokine milieu 
during HDC/autoSCT. Indeed, there have been several reports 
about increased cytokine concentrations during allogeneic and 
autologous SCT (16, 25, 30) shaping the NK cell phenotype. 
It has been reported that CD56+CD16++ NK cells are capable 
of up-regulating CD56 expression upon IL-15 (28) or IL-12 
stimulation (31), of which IL-15 is known to be increased dur-
ing HDC/autoSCT (16). Furthermore, different groups demon-
strated a downregulation of CD16 by metalloproteinases, which 
can be induced by IL-2 (32, 33). In general, the combined effect 
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of CD56 upregulation upon IL-15 stimulation and the loss of 
CD16 through IL-2-stimulated upregulation of metallopro-
teinases might result in the observed CD56++CD16+/− NK cell 
phenotype at TP2. Nevertheless, the CD56++ NK cells described 
in our study upregulated KIR3DL1 and KIR2DL2/3/S2, while 
KIR2DL1/S1 remained stable. KIR3DL1 and KIR2DL2/3 are 
the first KIRs expressed after SCT, whereas KIR2DL1 is upregu-
lated quite late (34, 35). Therefore, we could assume that the 
KIR upregulation was due to the generation of “fresh/new” NK 
cells and was not due to a shift of “old” NK cells to a CD56++ 
phenotype because we should have observed no changes within 
the KIR subtype distribution between TP1 and TP2 if the cells 
were derived from the “old” NK population. Moreover, we 
observed a slight upregulation of CX3CR1 at TP2 (data not 
shown). CX3CR1 expression is associated with a more mature 
and differentiated NK cell phenotype within healthy donors 
(36). In contrast to the observed CD56 upregulation, which can 
be explained by IL-15 stimulation (28), CX3CR1 is known to be 
downregulated upon IL-15 stimulation (36), which contradicts 
the idea that CD56++ NK cells with a mature phenotype (CD57+, 
CX3CR1+, and KIR+) have arisen from CD56dim NK cells. In 
future studies, it would be very interesting to investigate which 
factors are responsible for this NK cell phenotype because 
protocols for inducing NK cell maturation and differentiation 
have yet to be optimized.
Most importantly, we analyzed NK cell functional activity 
directly after leukocyte recovery after HDC/autoSCT. Upon 
interaction with K562 tumor cells, the percentage of IFN-γ- and 
MIP-1β-positive CD56++CD16+/− NK cells did not differ between 
TP1 and TP2. This result demonstrates that NK cells are capable 
of recognizing tumor cells and inducing cytokine and chemokine 
production, even at a very early time point after HDC/autoSCT. 
Moreover, the degranulation capacity of the CD56+CD16++ NK 
cell subset, known to be mainly responsible for NK cell cytotoxic-
ity (37), remained stable throughout the whole time period until 
TP3, indicating that these NK cells were able to kill tumor cells 
at an early time point after SCT. This finding is consistent with 
other studies in which patients received allogeneic SCT. For 
example, in the setting of HLA-matched SCT after reduced-
intensity conditioning, it has been demonstrated that the NK cell 
degranulation and chemokine production capacity was similar 
to healthy controls as early as 1 month after SCT. In contrast to 
our data, IFN-γ production upon interaction with K562 cells was 
significantly reduced after SCT compared to healthy donors (26). 
These differences might be due to the use of immunosuppressive 
drugs such as CSA because it has been demonstrated that CSA is 
able to reduce IFN-γ production upon target-cell interaction (38), 
although a recent report has failed to demonstrate such an effect 
(39). Furthermore, we compared IFN-γ production upon interac-
tion with K562 cells before and after SCT and not directly with 
healthy control samples. Therefore, although we did not observe a 
significant decrease in IFN-γ-positive cells between TP1 and TP2, 
their percentage might be still significantly lower than in healthy 
controls. Additionally, we observed that the degranulation capac-
ity was influenced by the time period between SCT and TP2 
because patients with a time period >11 days had significantly 
reduced CD107a-positive CD56+CD16++ cells at TP2. Because 
the prolonged time from SCT to TP2 indicates a longer period for 
leukocyte recovery, this might give an explanation for the reduced 
degranulation capacity. Nevertheless, we could not discover 
a correlation between NK cell function at TP2 and the rate of 
recurrent/refractory disease at 1 year after SCT, which might be 
due to the low number of recurrent/refractory patients and the 
short follow-up period.
To the best of our knowledge, this is the first study investi-
gating NK cell function at such an early time point after HDC/
autoSCT. We were able to demonstrate that NK cells were capable 
of cytokine/chemokine production and degranulation upon 
tumor cell interaction. Furthermore, we describe an unusual 
CD56++ NK cell population expressing high levels of CD57 and 
KIRs shortly after SCT. Further analysis and characterization 
of this population might reveal more details about how NK cell 
maturation and differentiation are regulated.
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